Study on GLP-1 for type 1 diabetes withdrawn before it began
NCT ID NCT04355832
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study planned to test whether a drug called glucagon-like peptide-1 (GLP-1) could protect blood vessels from damage caused by repeated low blood sugar in people with type 1 diabetes. The researchers aimed to enroll 40 adults aged 18–50. However, the study was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glucagon-like peptide-1 (GLP-1)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Maryland
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World test of automated insulin system aims to improve blood sugar control for type 1 diabetes
- Can a wearable sensor help young people with type 1 diabetes tame blood sugar swings?
- Can a smartphone app help teens tame type 1 diabetes?
- Smartphone nursing visits could transform diabetes care for teenagers
- New glucose monitor aims for pinpoint accuracy in diabetes care
- Blood clues: could type 1 diabetes change how children's blood works?